Latest filings (excl ownership)
8-K
23andMe announces CEO’s intention to pursue a potential take-private
18 Apr 24
8-K
Departure of Directors or Certain Officers
29 Mar 24
S-8
Registration of securities for employees
22 Mar 24
10-Q
2024 Q3
Quarterly report
7 Feb 24
8-K
23andMe Reports Third Quarter Fiscal 2024 Financial Results
7 Feb 24
8-K
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
31 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K/A
Regulation FD Disclosure
1 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Nov 23
8-K
23andMe Reports Second Quarter Fiscal 2024 Financial Results
8 Nov 23
10-Q
2024 Q2
Quarterly report
8 Nov 23
8-K
23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
6 Nov 23
8-K
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
30 Oct 23
8-K
Departure of Directors or Certain Officers
27 Oct 23
8-K
Regulation FD Disclosure
10 Oct 23
8-K
Departure of Directors or Certain Officers
19 Sep 23
S-8
Registration of securities for employees
15 Sep 23
8-K
Departure of Directors or Certain Officers
11 Sep 23
8-K
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
1 Sep 23
10-Q
2024 Q1
Quarterly report
8 Aug 23
8-K
23andMe Reports FY2024 First Quarter Financial Results
8 Aug 23
DEFR14A
Revised proxy
4 Aug 23
DEFR14A
Revised proxy
26 Jul 23
ARS
2023 FY
Annual report to shareholders
26 Jul 23
DEFA14A
Additional proxy soliciting materials
26 Jul 23
DEF 14A
Definitive proxy
26 Jul 23
8-K
Cost Associated with Exit or Disposal Activities
9 Jun 23
10-K
2023 FY
Annual report
25 May 23
8-K
23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results
25 May 23
8-K
Regulation FD Disclosure
17 Apr 23
8-K
23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
14 Apr 23
S-8
Registration of securities for employees
3 Mar 23
EFFECT
Notice of effectiveness
3 Mar 23
424B3
Prospectus supplement
2 Mar 23
424B3
Prospectus supplement
2 Mar 23
CORRESP
Correspondence with SEC
27 Feb 23
UPLOAD
Letter from SEC
9 Feb 23
10-Q
2023 Q3
Quarterly report
8 Feb 23
8-K
23andMe Reports FY2023 Third Quarter Financial Results
8 Feb 23
8-K
Other Events
6 Feb 23
Latest ownership filings
4
KATHY L HIBBS
19 Apr 24
SC 13D/A
ABeeC 2.0, LLC
17 Apr 24
4
KATHY L HIBBS
5 Apr 24
4
KATHY L HIBBS
22 Mar 24
4
KATHY L HIBBS
11 Mar 24
144
Notice of proposed sale of securities
7 Mar 24
4
KATHY L HIBBS
23 Feb 24
4
William G Richards
21 Feb 24
4
Joseph Anthony Selsavage
21 Feb 24
4
KATHY L HIBBS
21 Feb 24
4
KATHY L HIBBS
16 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13D/A
GSK plc
9 Feb 24
4
KATHY L HIBBS
26 Jan 24
SC 13G
BlackRock Inc.
26 Jan 24
4
KATHY L HIBBS
12 Jan 24
4
KATHY L HIBBS
29 Dec 23
4
KATHY L HIBBS
18 Dec 23
4
KATHY L HIBBS
1 Dec 23
144
Notice of proposed sale of securities
30 Nov 23
4
KATHY L HIBBS
21 Nov 23
4
William G Richards
21 Nov 23
4
Joseph Anthony Selsavage
21 Nov 23
4
KATHY L HIBBS
17 Nov 23
4
KATHY L HIBBS
3 Nov 23
144
Notice of proposed sale of securities
2 Nov 23
4
KATHY L HIBBS
20 Oct 23
144
Notice of proposed sale of securities
19 Oct 23
4
KATHY L HIBBS
6 Oct 23
144
Notice of proposed sale of securities
5 Oct 23
4
KATHY L HIBBS
25 Sep 23
144
Notice of proposed sale of securities
21 Sep 23
4
Anne Wojcicki
19 Sep 23
4
Joseph Anthony Selsavage
19 Sep 23
4
William G Richards
19 Sep 23
4
KATHY L HIBBS
19 Sep 23
4
KATHY L HIBBS
11 Sep 23
4
Sandra R MD Hernandez
8 Sep 23
4
RICHARD H SCHELLER
8 Sep 23
4
RICE VALERIE MD MONTGOMERY
8 Sep 23